Patents by Inventor Serge Van Calenbergh
Serge Van Calenbergh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11072628Abstract: The present invention relates to novel nucleoside analogues and compositions containing said nucleoside analogues. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the diagnosis, prevention and/or treatment of parasitic infections, more specifically for use in the diagnosis, prevention and/or treatment of a Trypanosoma infection.Type: GrantFiled: October 3, 2018Date of Patent: July 27, 2021Assignees: Universiteit Gent, Universiteit AntwerpenInventors: Fabian Hulpia, Serge Van Calenbergh, Guy Caljon, Louis Maes
-
Publication number: 20210024566Abstract: The present invention relates to novel nucleoside analogues and compositions containing said nucleoside analogues. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the diagnosis, prevention and/or treatment of parasitic infections, more specifically for use in the diagnosis, prevention and/or treatment of a Trypanosoma infection.Type: ApplicationFiled: October 3, 2018Publication date: January 28, 2021Inventors: Fabian Hulpia, Serge Van Calenbergh, Guy Caljon, Louis Maes
-
Patent number: 10723750Abstract: The compounds, compositions and methods provided herein antagonize, inhibit, decrease, reduce, suppress, or disrupt CD1d-mediated, iNKT cell-mediated, and/or iNKT cell TCR-mediated immune signaling. The sphingamide compounds were rationally designed based upon 3D structural considerations in relation to the structures of each of CD1d, the iNKT cell TCR, and the ternary complex CD1d-a-GalCer analog lipids-TCR. More specifically, the addition of an amide in the phytosphingosine tail of a derivative of ?-GalCer led to a non-conserved binding with CD1d, a conserved binding with the iNKT cell TCR, and an antagonist-like phenotype.Type: GrantFiled: November 14, 2016Date of Patent: July 28, 2020Assignees: La Jolla Institute for Allergy and Immunology, Universiteit Gent, VIB VZWInventors: Dirk Zajonc, Serge Van Calenbergh, Dirk Elewaut, Joren Guillaume
-
Publication number: 20190256541Abstract: The compounds, compositions and methods provided herein antagonize, inhibit, decrease, reduce, suppress, or disrupt CD1d-mediated, iNKT cell-mediated, and/or iNKT cell TCR-mediated immune signaling. The sphingamide compounds were rationally designed based upon 3D structural considerations in relation to the structures of each of CD1d, the iNKT cell TCR, and the ternary complex CD1d-a-GalCer analog lipids-TCR. More specifically, the addition of an amide in the phytosphingosine tail of a derivative of ?-GalCer led to a non-conserved binding with CD1d, a conserved binding with the iNKT cell TCR, and an antagonist-like phenotype.Type: ApplicationFiled: November 14, 2016Publication date: August 22, 2019Applicants: La Jolla Institute for Allergy and Immunology, Universiteit Gent, VIB VZWInventors: Dirk Zajonc, Serge Van Calenbergh, Dirk Elewaut, Joren Guillaume
-
Patent number: 10023602Abstract: The present invention relates to hamamelitannin analogues, pharmaceutical compositions comprising the same, and combinations thereof with anti-microbial agents such as antibiotics or disinfectants. It in particular relates to the use of the compounds, compositions and combinations according to this invention in human or veterinary medicine, more in particular for use in the prevention and/or treatment of bacterial infections, such as Staphylococcus aureus infections, in humans or animals.Type: GrantFiled: July 6, 2015Date of Patent: July 17, 2018Assignee: UNIVERSITEIT GENTInventors: Tom Coenye, Gilles Brackman, Martijn Risseeuw, Arno Vermote, Serge Van Calenbergh
-
Publication number: 20170158727Abstract: The present invention relates to hamamelitannin analogues, pharmaceutical compositions comprising the same, and combinations thereof with anti-microbial agents such as antibiotics or disinfectants. It in particular relates to the use of the compounds, compositions and combinations according to this invention in human or veterinary medicine, more in particular for use in the prevention and/or treatment of bacterial infections, such as Staphylococcus aureus infections, in humans or animals.Type: ApplicationFiled: July 6, 2015Publication date: June 8, 2017Applicant: Universiteit GentInventors: Tom Coenye, Gilles Brackman, Martijn Risseeuw, Arno Vermote, Serge Van Calenbergh
-
Patent number: 9321796Abstract: This invention relates to carbamate-containing or thiocarbamate-containing galacto-pyranosyl compounds useful as therapeutic agents and being represented by the structural formula (II), wherein: X is O or S, R is selected from the group consisting of C1-8 alkyl, C3-10 cycloalkyl, aryl-C1-4 alkyl, heterocyclyl-C1-4 alkyl, cycloalkyl-C1-4 alkyl, aryl and heterocyclyl, wherein R is optionally substituted with one or more R9; R2, R3, R4, R6 and R7 are independently selected from the group consisting of hydroxyl and protected hydroxyl groups; R5 is selected from the group consisting C6-30 alkyl and arylalkyl; R8 is C6-30 alkyl; and each R9 is independently selected from the group consisting of halogen, hydroxy, trifluoromethyl, trifluoromethoxy, C1-8alkoxy, C1-6 alkyl, cyano, methylthio, phenyl, phenoxy, chloromethyl, dichloromethyl, chloro-difluoromethyl, acetyl, nitro, benzyl, heterocyclyl and di-C1-4 alkyl-amino, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 20, 2013Date of Patent: April 26, 2016Assignee: Universiteit GentInventors: Dirk Elewaut, Nora Pauwels, Sandrine Aspeslagh, Serge Van Calenbergh
-
Publication number: 20150210728Abstract: This invention relates to carbamate-containing or thiocarbamate-containing galacto-pyranosyl compounds useful as therapeutic agents and being represented by the structural formula (II), wherein: X is O or S, R is selected from the group consisting of C1-8 alkyl, C3-10 cycloalkyl, aryl-C1-4 alkyl, heterocyclyl-C1-4 alkyl, cycloalkyl-C1-4 alkyl, aryl and heterocyclyl, wherein R is optionally substituted with one or more R9; R2, R3, R4, R6 and R7 are independently selected from the group consisting of hydroxyl and protected hydroxyl groups; R5 is selected from the group consisting C6-30 alkyl and arylalkyl; R8 is C6-30 alkyl; and each R9 is independently selected from the group consisting of halogen, hydroxy, trifluoromethyl, trifluoromethoxy, C1-8alkoxy, C1-6 alkyl, cyano, methylthio, phenyl, phenoxy, chloromethyl, dichloromethyl, chloro-difluoromethyl, acetyl, nitro, benzyl, heterocyclyl and di-C1-4 alkyl-amino, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 20, 2013Publication date: July 30, 2015Inventors: Dirk Elewaut, Nora Pauwels, Sandrine Aspeslagh, Serge Van Calenbergh
-
Publication number: 20130046087Abstract: The present invention relates to substituted cyclodextrin derivatives which are particularly useful intermediates for producing well-defined carboxyalkylated cyclodextrins in contrast with the poorly-defined mixtures available through prior art procedures. The present invention also relates to processes for their preparation in a limited number of steps. These well-defined carboxyalkylated cyclodextrins can be polysulfated according to procedures standard in the art and some of these polysulfates, and alkali salts thereof, have been found to exhibit biologically active properties especially for the treatment and/or prophylaxis of degenerative joint diseases (e.g. osteoarthritis) or heparin-induced thrombocytopenia, or for cartilage repair or connective tissue repair.Type: ApplicationFiled: March 23, 2011Publication date: February 21, 2013Applicant: Arcarios BVInventors: Serge Van Calenbergh, Kiran Toti, Eric Wilhelmus Petrus Damen
-
Patent number: 8039501Abstract: This invention provides compounds having the structural formula: wherein: R1 is an acyl or sulfonyl group, R2 is an acyl group selected from the group consisting of acyl groups derived from cycloaliphatic, aromatic or heterocyclic monocarboxylic acids, imidazolylcarbonyl and triazolylcarbonyl, and R3 is hydrogen or an amino-protecting group, a stereoisomer thereof, a solvate thereof, or a salt thereof, being useful as anti-inflammatory agents and anti-cancer agents.Type: GrantFiled: June 23, 2008Date of Patent: October 18, 2011Assignee: Universiteit GentInventors: Wim Vanden Berghe, Karolien De Bosscher, Serge Van Calenbergh, Guy Haegeman, Carl Jeffrey Lacey
-
Patent number: 7638505Abstract: The present invention relates to novel phosphonic acid compounds having the structural formula (I): wherein: (a) R is a group of 1 to 5 substituents independently selected from the group consisting of fluoro, chloro, bromo, C1-4 alkoxy, C1-4 alkyl, hydroxy, formyl, trifluoromethoxy, phenyl, heterocyclic, heterocyclic-substituted methyl, aminomethyl, hydroxy methyl, bromomethyl, sulfonyl chloride, acetyl chloride, nitroso and cyano, (b) R1 is selected from the group consisting of hydrogen, C1-7 alkyl, C3-10 cycloalkyl, aryl, arylalkyl and heterocyclic, and (c) R2 is selected from the group consisting of hydroxy and hydroxy-protecting groups, and stereoisomer, solvates and salts thereof. These compounds are useful as anti-infectious and anti-parasitic agents, in particular anti-malaria agents.Type: GrantFiled: December 22, 2006Date of Patent: December 29, 2009Assignee: Universiteit GentInventors: Serge Van Calenbergh, Timothy Haemers, Vincent Devreux, Hassan Jomaa, Jochen Wiesner
-
Publication number: 20090029999Abstract: This invention provides compounds having the structural formula: wherein: R1 is an acyl or sulfonyl group, R2 is an acyl group selected from the group consisting of acyl groups derived from cycloaliphatic, aromatic or heterocyclic monocarboxylic acids, imidazolylcarbonyl and triazolylcarbonyl, and R3 is hydrogen or an amino-protecting group, a stereoisomer thereof, a solvate thereof, or a salt thereof, being useful as anti-inflammatory agents and anti-cancer agents.Type: ApplicationFiled: June 23, 2008Publication date: January 29, 2009Applicant: UNIVERSITEIT GENTInventors: Wim VANDEN BERGHE, Karolien DE Bosscher, Serge Van Calenbergh, Guy Haegeman, Carl Jeffrey Lacey, Valerie Gossye, Ruben Hoya Arias, Sarah Gerlo
-
Publication number: 20080312190Abstract: The present invention relates to novel phosphonic acid compounds having the structural formula (I): wherein: (a) R is a group of 1 to 5 substituents independently selected from the group consisting of fluoro, chloro, bromo, C1-4 alkoxy, C1-4 alkyl, hydroxy, formyl, trifluoromethoxy, phenyl, heterocyclic, heterocyclic-substituted methyl, aminomethyl, hydroxy methyl, bromomethyl, sulfonyl chloride, acetyl chloride, nitroso and cyano, (b) R1 is selected from the group consisting of hydrogen, C1-7 alkyl, C3-10 cycloalkyl, aryl, arylalkyl and heterocyclic, and (c) R2 is selected from the group consisting of hydroxy and hydroxy-protecting groups, and stereoisomer, solvates and salts thereof. These compounds are useful as anti-infectious and anti-parasitic agents, in particular anti-malaria agents.Type: ApplicationFiled: December 22, 2006Publication date: December 18, 2008Applicant: UNIVERSITEIT GENTInventors: Serge Van Calenbergh, Timothy Haemers, Vincent Devreux, Hassan Jomaa, Jochen Wiesner